BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 339 filers reported holding BIO-TECHNE CORP in Q2 2018. The put-call ratio across all filers is 3.84 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,208 | -53.4% | 16,296 | -47.9% | 0.05% | -56.8% |
| Q4 2022 | $2,592 | -99.9% | 31,284 | +298.3% | 0.12% | +16.8% |
| Q3 2022 | $2,231,000 | -37.5% | 7,854 | -23.7% | 0.11% | -31.4% |
| Q2 2022 | $3,567,000 | -36.6% | 10,290 | -20.8% | 0.16% | -29.7% |
| Q1 2022 | $5,625,000 | -17.6% | 12,990 | -1.5% | 0.22% | +5.7% |
| Q4 2021 | $6,823,000 | -2.8% | 13,190 | -9.0% | 0.21% | -7.5% |
| Q3 2021 | $7,022,000 | -3.1% | 14,490 | -10.0% | 0.23% | -5.8% |
| Q2 2021 | $7,249,000 | +17.9% | 16,099 | 0.0% | 0.24% | +11.1% |
| Q1 2021 | $6,148,000 | +24.2% | 16,099 | +3.3% | 0.22% | +28.4% |
| Q4 2020 | $4,951,000 | +28.2% | 15,590 | 0.0% | 0.17% | +34.1% |
| Q3 2020 | $3,862,000 | -9.2% | 15,590 | -3.2% | 0.13% | +8.6% |
| Q2 2020 | $4,251,000 | +50.5% | 16,100 | +8.1% | 0.12% | +38.1% |
| Q1 2020 | $2,825,000 | -7.4% | 14,900 | +7.2% | 0.08% | +20.0% |
| Q4 2019 | $3,051,000 | +9.0% | 13,900 | -2.8% | 0.07% | +11.1% |
| Q3 2019 | $2,798,000 | +12.4% | 14,300 | -13.2% | 0.06% | +46.5% |
| Q1 2018 | $2,489,000 | – | 16,475 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |